While there are fears, accusations, and criticism that the final Good Reprint Practices guidance document will allow drug and device companies to now “promote off-label uses,” this is not at all the case. Such views represent a fundamental misunderstanding of the plain language of the final guidance document, a fundamental misunderstanding of the extent of [...]